{"log_id": 4239955615949153082, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 3e-06, "average": 0.998135, "min": 0.995638}, "location": {"width": 96, "top": 173, "height": 48, "left": 156}, "words": "6个月"}, {"probability": {"variance": 6e-06, "average": 0.996424, "min": 0.993962}, "location": {"width": 21, "top": 177, "height": 23, "left": 567}, "words": "23"}, {"probability": {"variance": 0.074185, "average": 0.806629, "min": 0.366312}, "location": {"width": 91, "top": 214, "height": 23, "left": 203}, "words": "850反应"}, {"probability": {"variance": 0, "average": 0.999702, "min": 0.99943}, "location": {"width": 41, "top": 250, "height": 22, "left": 185}, "words": "2周"}, {"probability": {"variance": 0, "average": 0.999079, "min": 0.999032}, "location": {"width": 20, "top": 276, "height": 19, "left": 867}, "words": "45"}, {"probability": {"variance": 0.008663, "average": 0.934024, "min": 0.802395}, "location": {"width": 42, "top": 178, "height": 137, "left": 1152}, "words": "管章一"}, {"probability": {"variance": 0, "average": 0.999663, "min": 0.999108}, "location": {"width": 60, "top": 283, "height": 24, "left": 185}, "words": "3个月"}, {"probability": {"variance": 0, "average": 0.999843, "min": 0.999778}, "location": {"width": 57, "top": 318, "height": 24, "left": 187}, "words": "6个月"}, {"probability": {"variance": 0.001768, "average": 0.976976, "min": 0.883215}, "location": {"width": 106, "top": 352, "height": 24, "left": 188}, "words": "AS70反应"}, {"probability": {"variance": 0, "average": 0.804364, "min": 0.804364}, "location": {"width": 23, "top": 373, "height": 23, "left": 877}, "words": " 2D"}, {"probability": {"variance": 0, "average": 0.999441, "min": 0.999308}, "location": {"width": 39, "top": 387, "height": 23, "left": 186}, "words": "2周"}, {"probability": {"variance": 0, "average": 0.999655, "min": 0.999445}, "location": {"width": 61, "top": 420, "height": 22, "left": 183}, "words": "3个月"}, {"probability": {"variance": 0, "average": 0.999344, "min": 0.999209}, "location": {"width": 23, "top": 410, "height": 22, "left": 868}, "words": "29"}, {"probability": {"variance": 0, "average": 0.999746, "min": 0.99972}, "location": {"width": 42, "top": 455, "height": 23, "left": 202}, "words": "个月"}, {"probability": {"variance": 0, "average": 0.998532, "min": 0.99835}, "location": {"width": 23, "top": 444, "height": 23, "left": 869}, "words": "28"}, {"probability": {"variance": 0.002206, "average": 0.984255, "min": 0.803556}, "location": {"width": 283, "top": 481, "height": 34, "left": 212}, "words": "0.001,依那西普与安慰剂比较"}, {"probability": {"variance": 3e-06, "average": 0.99841, "min": 0.994478}, "location": {"width": 262, "top": 518, "height": 26, "left": 233}, "words": "002,依那西普与安慰剂比较"}, {"probability": {"variance": 4e-06, "average": 0.999051, "min": 0.989336}, "location": {"width": 817, "top": 548, "height": 43, "left": 209}, "words": "在接受依那西普治疗的强直性脊柱炎患者在第一次访视时(第2周)即出现临床反"}, {"probability": {"variance": 1e-06, "average": 0.999229, "min": 0.996582}, "location": {"width": 863, "top": 596, "height": 45, "left": 164}, "words": "应,并在6个月的治疗期间一直保持不变。基线期接受药物联合治疗的和不联合用药的"}, {"probability": {"variance": 0, "average": 0.999693, "min": 0.998718}, "location": {"width": 209, "top": 660, "height": 27, "left": 165}, "words": "患者,临床疗效相似"}, {"probability": {"variance": 1e-06, "average": 0.999168, "min": 0.996278}, "location": {"width": 550, "top": 699, "height": 41, "left": 209}, "words": "在两个较小的强直性脊柱炎试验中也获得了类似的结果"}, {"probability": {"variance": 2.5e-05, "average": 0.997044, "min": 0.977767}, "location": {"width": 819, "top": 743, "height": 47, "left": 209}, "words": "第4项双盲、安慰剂对照的试验中入组了活动期强直性脊柱炎患者356例,评价给"}, {"probability": {"variance": 0.001399, "average": 0.991371, "min": 0.754487}, "location": {"width": 864, "top": 793, "height": 46, "left": 165}, "words": "药方案为50mg(25×2)每周1次皮下给药与25mg每周2次皮下给药的安全性和有效"}, {"probability": {"variance": 9.6e-05, "average": 0.99485, "min": 0.95057}, "location": {"width": 711, "top": 846, "height": 40, "left": 164}, "words": "性。50mg每周1次与25mg每周2次给药的安全性和有效性特点相似。"}, {"probability": {"variance": 0.000849, "average": 0.984185, "min": 0.92593}, "location": {"width": 100, "top": 955, "height": 27, "left": 168}, "words": "[药理毒理"}, {"probability": {"variance": 0.086068, "average": 0.792264, "min": 0.377371}, "location": {"width": 174, "top": 932, "height": 62, "left": 702}, "words": "医药"}, {"probability": {"variance": 2e-06, "average": 0.998912, "min": 0.995212}, "location": {"width": 807, "top": 986, "height": 47, "left": 209}, "words": "药理作用:类风湿关节炎和强直性脊柱炎的关节病理多数是由前炎性分子介导的"}, {"probability": {"variance": 0.000806, "average": 0.992169, "min": 0.81936}, "location": {"width": 869, "top": 1034, "height": 48, "left": 163}, "words": "这些分子与一个由肿瘤坏死因子(TNF)控制的网络相联系。TNF是类风湿性关节炎炎"}, {"probability": {"variance": 2.3e-05, "average": 0.997568, "min": 0.976736}, "location": {"width": 868, "top": 1084, "height": 46, "left": 163}, "words": "性反应中一起主导作用的细胞因子。在强直性脊柱炎患者的血清和滑膜组织也可以发现"}, {"probability": {"variance": 0.000112, "average": 0.996072, "min": 0.940671}, "location": {"width": 869, "top": 1131, "height": 47, "left": 165}, "words": "TNF水平升高。依那西普是细胞表面TNF受体的竞争性抑制剂,可以抑制TNF的生物"}, {"probability": {"variance": 0.000192, "average": 0.995789, "min": 0.915685}, "location": {"width": 872, "top": 1180, "height": 47, "left": 162}, "words": "活性,从而阻断了TNF介导的细胞反应。依那西普可能还参与调节由TNF诱导或调节"}, {"probability": {"variance": 0.000278, "average": 0.995674, "min": 0.904726}, "location": {"width": 718, "top": 1232, "height": 44, "left": 164}, "words": "的其它下游分子(如:细胞因子、黏附分子或蛋白酶)控制的生物反应"}, {"probability": {"variance": 0.00273, "average": 0.989087, "min": 0.668214}, "location": {"width": 825, "top": 1278, "height": 46, "left": 211}, "words": "INF是前炎性细胞因子,结合于两个不同的细胞表面受体:55千道尔顿(p55)和"}, {"probability": {"variance": 0.001111, "average": 0.987202, "min": 0.838299}, "location": {"width": 871, "top": 1328, "height": 46, "left": 165}, "words": "75千道尔顿(p75)的肿瘤坏死因子受体(TNFR)。两种TNFR自然状态下都以膜结合的"}, {"probability": {"variance": 8.7e-05, "average": 0.996185, "min": 0.950403}, "location": {"width": 685, "top": 1380, "height": 43, "left": 164}, "words": "和可溶的形式存在。可溶性TNFR被认为可以调节TNF的生物活性"}, {"probability": {"variance": 0.003949, "average": 0.986074, "min": 0.614288}, "location": {"width": 822, "top": 1425, "height": 45, "left": 213}, "words": "INF主要以同型三聚体的形式存在,它们的生物活性依赖于与细胞表面TNFR的交"}, {"probability": {"variance": 3.3e-05, "average": 0.997579, "min": 0.969465}, "location": {"width": 864, "top": 1474, "height": 46, "left": 164}, "words": "联。与受体单体相比,可溶性受体二聚体(如:依那西普)对TNF具有更高的亲和力"}, {"probability": {"variance": 2e-06, "average": 0.99907, "min": 0.994042}, "location": {"width": 872, "top": 1523, "height": 45, "left": 164}, "words": "被认为是对TNF结合于其细胞受体的更有效的竞争性抑制剂。除此之外,利用一个免"}, {"probability": {"variance": 4e-06, "average": 0.998923, "min": 0.98763}, "location": {"width": 803, "top": 1572, "height": 46, "left": 164}, "words": "疫球蛋白的Fc区域作为融合元件以使构建的二聚体受体得到更长的血清半衰期"}, {"probability": {"variance": 0.000126, "average": 0.992842, "min": 0.964087}, "location": {"width": 127, "top": 1658, "height": 25, "left": 165}, "words": "版本号:20090"}, {"probability": {"variance": 1e-05, "average": 0.996909, "min": 0.990686}, "location": {"width": 179, "top": 1644, "height": 28, "left": 777}, "words": "第20页共31页"}], "language": 3}